Where Opportunity is Found – Research on AcelRx Pharmaceuticals, Tandem Diabetes Care, Brightcove and SciQuest

NEW YORK, NY / ACCESSWIRE / November 2, 2015 / Moments ago, Trader’s Choice released new research updates concerning several important developing situations including the following equities: AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Tandem Diabetes Care Inc. (NASDAQ: TNDM), Brightcove Inc. (NASDAQ: BCOV) and SciQuest, Inc. (NASDAQ: SQI). Trader’s Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.

To access our full PDF reports for free, please visit the links below.

============

Full PDF DOWNLOAD Links

(You may have to copy and paste the links into your browser)

ACRX Research Report: http://www.traders-choice.com/pdf?s=ACRX

TNDM Research Report: http://www.traders-choice.com/pdf?s=TNDM

BCOV Research Report: http://www.traders-choice.com/pdf?s=BCOV

SQI Research Report: http://www.traders-choice.com/pdf?s=SQI

============

Highlights from today’s reports include:

On Friday, October 30, 2015, the NASDAQ Composite ended at 5,053.75, down 0.40%, the Dow Jones Industrial Average edged 0.52% lower, to finish the day at 17,663.54, and the S&P 500 closed at 2,079.36, down 0.48%.

– The stock of AcelRx Pharmaceuticals Inc. gained 17.61% to close Friday’s session at USD 3.94. The shares of the company moved in the range of USD 3.61 and USD 4.00 during the day. A trading volume of 3.64 million shares was recorded, which was greater than its 150-day daily average volume of 0.57 million shares and above its 52-week average volume of 0.57 million shares. Over the last five days, AcelRx Pharmaceuticals Inc.’s shares have advanced 17.96% and in the past one month, they have gained a momentum of 29.18%. Additionally, over the last three months, the stock has declined 4.37% and in the past six months, the shares have registered a loss of 2.23%. The company has generated a negative return of 40.57% in the last year on a compounded total return basis. The stock is trading at a price to book ratio of 4.45 while the historical PB ratio is close to 6.31. Further, the stock is trading at a price to sales ratio of 20.77.

– Tandem Diabetes Care Inc.’s stock increased by 18.25% to close Friday’s session at USD 9.07. The company’s shares fluctuated in the range of USD 7.80 and USD 9.75 during the day. A total of 1.17 million shares exchanged hands, which surpassed its 50-day daily average volume of 0.23 million shares and was above its 52-week average volume of 0.19 million shares. Over the last three days Tandem Diabetes Care Inc.’s shares have advanced 20.13% and in the past one week it has moved up 14.38%. Furthermore, over the last three months, the stock has lost 27.73% and in the past six months, the shares have shed 33.84%. The company has returned 2.95% in the past month, and generated a negative return of 43.52% in the last year, on a compounded total return basis. The stock is trading at a price to book ratio of 2.62 which compares to a historical PB ratio close to 5.50. Additionally, the stock is trading at a price sales ratio of 3.87.

– Brightcove Inc.’s stock added 15.03% to close Friday’s session at USD 6.20. The company’s shares oscillated between USD 5.85 and USD 6.42 in trade during the day. The stock recorded a trading volume of 0.46 million shares, which was above its 50-day daily average volume of 0.13 million shares and above its 52-week average volume of 0.19 million shares. Over the last five days, Brightcove Inc.’s shares have advanced 17.20% and in the past one month, it has gained a momentum of 26.02%. In addition, over the last three months, the stock has gained 13.35% and year to date, the shares have shed 20.31%. The stock is trading 16.39% and 18.05% above its 20-day and 50-day simple moving averages. However, the stock is trading 5.91% below its 200-day simple moving average. Additionally, Brightcove Inc.’s stock is trading at a price to cash flow ratio of 9.51 while its price to book ratio is 2.62.

– SciQuest Inc.’s stock advanced 15.93% to close Friday’s session at USD 11.86. The share price vacillated between USD 10.31 and USD 11.95 in trade during the day. The stock recorded a trading volume of 0.60 million shares, which was above its 50-day daily average volume of 0.22 million shares and above its 52-week average volume of 0.16 million shares. Over the last three days SciQuest Inc.’s shares have advanced 21.02% and in the past one week it has moved up 19.80%. Moreover, in the last six months, the stock has lost 25.64% and year to date, the shares have shed 17.92%. SciQuest Inc.’s stock has shown positive movement and is trading 13.5% and 8.84% above its 20-day and 50-day simple moving averages. However, the stock is trading 16.01% below its 200-day simple moving average. Further, the company’s stock is trading at a price to sales ratio of 3.18 and a price to book ratio of 1.77.

About Trader’s Choice:

Trader’s Choice (“TC”) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TC has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the “Production Team”) in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.

NO WARRANTY

TC, the Author and the Reviewer (collectively referred to as the “Publishers”) are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.

RESTRICTIONS

TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

E-mail: press (at) traders-choice.com

SOURCE: Trader’s Choice

ReleaseID: 433144